Immunomodulation in the critically ill

British Journal of Anaesthesia

Volumn 103, Issue 1, 2009, Pages 70-81

  Webster, N R ^a   Galley, H F ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cytokines; Immune system; Intensive care; Respiratory distress system, adult; Systemic inflammatory response system

Indexed keywords

ACTIVATED PROTEIN C; ATLIZUMAB; BETAMETHASONE; CORTICOSTEROID DERIVATIVE; CYTOKINE; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR ANTAGONIST; ENDOTOXIN ANTIBODY; ETANERCEPT; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MACROLIDE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEDATIVE AGENT; STEROID; IMMUNOLOGIC FACTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; BACTEREMIA; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRITICAL ILLNESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; GENE TARGETING; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCIDENCE; INFECTION; INTENSIVE CARE UNIT; LOW DRUG DOSE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRAUMATIC BRAIN INJURY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG ANTAGONISM; IMMUNOLOGY; METHODOLOGY;

CRITICAL ILLNESS; CYTOKINES; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 67650738740     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep128     Document Type: Review

References (85)

1. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351: 929-33
2. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifaco-gin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc 2003; 290: 238-47
3. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. J Am Med Assoc 1995; 273: 934-41
4. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-5
5. Annane D. Glucocorticoids in the treatment of severe sepsis and septic shock. Curr Opin Crit Care 2005; 11: 449-53
6. Annane D, Sebille V, Bollaert PE, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. J Am Med Assoc 2002; 288: 862-71
7. ARDSnet. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301-8
8. Barnes PJ. How corticosteroids control inflammation: quintiles prize lecture 2005. Br J Pharmacol 2006; 148: 245-54
9. Bernard GR, Artigas A, Brigham KL, et al. The American- European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-24
10. Bernard GR, Luce JM, Sprung CL, et al. High dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317: 1565-70
11. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for sepsis. N Engl J Med 2001; 344: 699-709
12. Bone RC, Balk RA, Cerra FB, et al. ACCP/SCCM consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-55
13. Boontham P, Chandran P, Rowlands B, Eremin O. Surgical sepsis: dysregulation of immune function and therapeutic implications. Surg J R Coll Surg Edinb Irel 2003; 1: 187-206
14. Cabot PJ. Immune-derived opioids and peripheral antinocicep-tion. Clin Exp Pharmacol Physiol 2001; 28: 230-2
15. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-40
16. Cowley HC, Heaney D, Gearing A, Webster NR. Increased circulating adhesion molecule concentrations in patients with the systemic inflammatory response syndrome: a prospective cohort study. Crit Care Med 1994; 22: 651-7
17. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-9
18. Dellinger RP, Levy MM, Carlet J, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 2008; 34: 17-60
19. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994; 22: 1720-8
20. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3: 678-81
21. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin 1 (IL-1) receptor antagonist binds to the 80 kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 10331-6
22. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166: 1197-205
23. Finfer S, Ranieri VM, Thompson BT, et al. Design, conduct, analysis and reporting of a multi-national placebo controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008; 34: 1935-47
24. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-702
25. Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human inter-leukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. J Am Med Assoc 1994; 271: 1836-43
26. Galley HF, Dhillon JK, Paterson RL, Webster NR. Effect of cipro-floxacin on the activation of the transcription factors NFκB, AP-1 and NF-IL-6, and interleukin-6 and interleukin-8 mRNA expression in a human endothelial cell line. Clin Sci 2000; 99: 405-10
27. Galley HF, Dubbels AM, Webster NR. The effect of midazolam and propofol on interleukin-8 from human polymorphonuclear leukocytes. Anesth Analg 1998; 86: 1289-93
28. Galley HF, El Sakka NE, Webster NR, Lowes DA, Cuthbertson BH. Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions. Br J Anaesth 2008; 100: 815-9
29. Galley HF, Nelson SJ, Dubbels AM, Webster NR. Effect of cipro-floxacin on the accumulation of interleukin-6, interleukin-8 and nitrite from an endothelial cell model of sepsis. Crit Care Med 1997; 25: 1392-5
30. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-80
31. Goode HF, Webster NR. Free radicals and antioxidants in sepsis. Crit Care Med 1993; 21: 1770-6
32. Heard SO, Fink MP, Gamelli RL, et al. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. Crit Care Med 1998; 26: 748-54
33. Huang HC, Shieh CC, Yu WL, et al. Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries. Respirology 2008; 13: 47-52
34. Huettemann E, Jung A, Vogelsang H, Hout N, Sakka SG. Effects of propofol vs methohexital on neutrophil function and immune status in critically ill patients. J Anesth 2006; 20: 86-91
35. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of blood stream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55
36. Inada T, Yamanouchi Y, Jomura S, et al. Effect of propofol and isoflurane anaesthesia on the immune response to surgery. Anaesthesia 2004; 59: 954-9
37. Jantz MA, Sahn SA. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med 1999; 160: 1079-100
38. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-203
39. Kertai MD, Boersma E, Klein J, van Urk H, Poldermans D. Optimising the prediction of perioperative mortality in vascular surgery by using a customized probability model. Arch Intern Med 2005; 165: 898-904
40. Klein B, Brailly H. Cytokine binding proteins: stimulating antagonists. Immunology Today 1995; 16: 216-20
41. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31: S131-8
42. LeCras AE, Galley HF, Webster NR. Spinal but not general anesthesia increases the ratio of T helper 1 to T helper 2 cell subsets in patients undergoing transurethral resection of the prostate. Anesth Analg 1998; 87: 1421-5
43. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23: 1294-303
44. Lowes DA, Thottakam BMVJ, Webster NR, Murphy MP, Galley HF. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Rad Biol Med 2008; 45: 1559-65
45. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138: 62-8
46. Mahdy AM, Galley HF, Abdel-Wahed MA, El-Korny KF, Sheta SA, Webster NR. Differential modulation of interleukin-6 and interleukin-10 by diclofenac in patients undergoing major surgery. Br J Anaesth 2002; 88: 797-802
47. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997; 25: 1813-9
48. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe acute respiratory distress syndrome: results of a randomised controlled trial. Chest 2007; 131: 954-63
49. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. N Engl J Med 1998; 280: 159-65
50. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998; 158: 1432-41
51. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methyl-prednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 165: 983-91
52. Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141: 47-56
53. Muchamuel T, Menon S, Pisacane P, Howard MC, Cockayne DA. IL-13 protects mice from lipopolysaccharide-induced lethal endo-toxemia: correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. J Immunol 1997; 158: 2898-903
54. Nasraway SA. The problems and challenges of immunotherapy in sepsis. Chest 2003; 123: 451S-9S
55. Nelson S, Heyder AM, Stone J, et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 2000; 182: 970-3
56. Ohlsson K, Bjork P, Bergenfeldt M. Interleukin 1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550-2
57. Opal SM, Fisher CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-24
58. Opal S, Laterre PF, Abraham E, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32: 332-41
59. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/ CARS continuum in sepsis and predict mortality. J Immunol 2006; 177: 1967-74
60. Perlmutter DH, Dinarello CA, Punsal PI, Cohen HR. Cachectin/ tumour necrosis factor regulates hepatic acute phase gene expression. J Clin Invest 1986; 78: 1349-54
61. Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. Br Med J 2008; 336: 1006-9
62. Pettila V, Takkunen O, Varpula T, et al. Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit: interim analysis of a prospective, placebo-controlled, double-blind study. Crit Care Med 2000; 28: 3620-5
63. Quante T, Ng YC, Ramsay EE, et al. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am J Respir Cell Mol Biol 2008; 39: 208-17
64. Reinhart K, Menges T, Garlund B, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29: 765-9
65. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutro-penic patients. J Infect Dis 1999; 179: S342-52
66. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353: 1685-93
67. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184: 333-41
68. Sharp BM, Roy S, Bidlack JM. Evidence for opioid receptors on cells involved in host defense and the immune system. J Neuroimmunol 1998; 83: 45-56
69. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-24
70. Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354: 1671-84
71. Stephan F, Yang K, Tankovic J, et al. Impairment of polymorpho-nuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 2002; 30: 315-22
72. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis 2006; 6: 242-8
73. Tracey K, Fong Y, Hesse DG. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4
74. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845-9
75. Vincent JL, Spapen H, Bakker J, Webster NR, Curtis L. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 2000; 28: 638-42
76. Volk HD, Reinke P, Docke WD. Clinical aspects: from systemic inflammation to immunoparalysis. Chem Immunol 2000; 74: 162-77
77. Wang J, Barke RA, Charboneau R, Loh HH, Roy S. Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem 2003; 278: 37622-31
78. Wang J, Barke RA, Roy S. Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine. J Biol Chem 2007; 282: 7164-71
79. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-49
80. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286: 1869-78
81. Weinert CR, Kethireddy S, Roy S. Opioids and infections in the intensive care unit should clinicians and patients be concerned? J Neuroimmune Pharmacol 2008; 3: 218-29
82. Weiss M, Gross-Weege W, Schneider M, et al. Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 1995; 10: 21-6
83. Williams AC, Galley HF, Watt AM, Webster NR. Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother 2005; 56: 502-6
84. Wunderink R, Leeper K, Schein R, et al. Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001; 119: 523-9
85. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30: 1118-22